ASCENT: Sacituzumab Govitecan in Triple Negative Breast Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

ASCENT: Sacituzumab Govitecan in Triple Negative Breast Cancer

Sponsor: Immunomedics, Inc.

Protocol IMMU-132-05: A trial in which an enrolled patient will be randomized to receive treatment with either Sacituzumab Govitecan or physician's choice of eribulin, capecitabine, gemcitabine, or vinorelbine. Patients must have been treated with at least two prior lines of chemotherapy for advanced or metastatic breast cancer, and must be ER, PR, and HER2 negative on their most recent pathology report.